Filtered By:
Source: Clinical Prostate Cancer
Drug: Zometa
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
CONCLUSION: The selective CatK inhibitor may prevent the establishment and progression of PCa in bone, thus making it a novel therapeutic approach for advanced PCa.
PMID: 31172267 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - June 5, 2019 Category: Cancer & Oncology Authors: Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J Tags: J Cancer Res Clin Oncol Source Type: research
